Cefetamet pivoxil treatment causes loss of carnitine reserves that can be prevented by exogenous carnitine administration

Journal of Nutritional Biochemistry

Volumn 10, Issue 11, 1999, Pages 670-673

  Pap, Maria ^a   Kopcsányi, Gábor ^a   Bieber, Loran L ^c   Gage, Douglas A ^c   Melegh, Béla ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Dept Med Genet Child D ^*  (Hungary)

^c Michigan State University   (United States)

Author keywords

Carnitine; Carnitine deficiency; Cefetamet pivoxil; Mass spectrometry; Pivalate

Indexed keywords

CARNITINE; CEFETAMET PIVOXIL; DRUG METABOLITE;

ADOLESCENT; ARTICLE; BACTERIURIA; BLOOD LEVEL; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINE VOLUME;

EID: 0344286725     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(99)00051-0     Document Type: Article

References (23)

1. Bieber L.L. Carnitine. Ann. Rev. Biochem. 57:1988;261-283.
2. Bieber L.L., Emaus R., Valkner K., Farrel S. Possible functions of short-chain and medium-chain carnitine acetyl-transferases. Fed. Proc. 41:1982;2858-2862.
3. Bremer J. Carnitine Metabolism and functions . Physiol. Rev. 63:1983;1440-1480.
4. Melegh B., Kerner J., Bieber L.L. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 36:1987;3405-3409.
5. Melegh B., Kerner J., Jaszai V., Bieber L.L. Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. Biochem. Med. Metab. Biol. 43:1990;30-38.
6. Quistad G.B., Staiger L.E., Schooley D.A. The role of carnitine in the conjugation of acidic xenobiotics. Drug Metab. Dispos. 14:1986;521-526.
7. Vickers S., Duncan C.A.H., White S.D., Ramjit H.G., Smith J.L., Walker R.W., Flynn H., Arrison B.H. Carnitine and glucuronic acid conjugates of pivalic acid. Xenobiotica. 15:1985;53-458.
8. Melegh B., Pap M., Molnar D., Masszi G., Kopcsanyi G. Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin treatment. Eur. J. Pediatr. 156:1997;759-799.
9. Diep Q.N., Bohmer T., Holme J.I., Torvik A., Storrosten O.T., Loeaecken C.V., Monstad P., Jellum E. Slow replenishment of carnitine deficiency after cessation of long-term treatment with pivaloyl-containing antibiotics. Pharm. World Sci. 15:1993;225-229.
10. Melegh B., Pap M., Morava E., Molnar D., Dani M., Kurucz J. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J. Pediatr. 125:1994;317-321.
11. Melegh B., Pap M., Szekely G., Gage D.A., Sherry A.D., Bieber L.L. No replenishment of carnitine from trimethyllysine during pivalate-induced carnitine loss in humans. J. Nutr. Biochem. 8:1997;147-151.
12. Melegh B., Sumegi B., Sherry A.D. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Xenobiotica. 23:1993;1255-1261.
13. Chibante A., Peixoto E., Lejeune R., Winter K., Kissling M. Clinical efficacy and safety of cefetamet pivoxil in toddlers. Int. J. Antimicrob. Agents. 4:1994;203-210.
14. Cullmann W. Comparative evaluation of orally active antibiotics against community-acquired pathogens Results of eight European countries . Chemotherapy. 42:1996;11-20.
15. Dagan R., Syrogiannopoulos G., Ashkenazi S., Engelhard D., Einhorn M., Gatzolakaravelli M., Shalit T., Amir J. Parenteral-oral switch in the management of pediatric pneumonia. Drugs. 47:(suppl):1994;43-51.
16. Hanson A.D., Rathinasabapathi B., Rivoal J., Burnet M., Dillon M.O., Gage D. Osmoprotective compounds in the Plumbaginaceae A natural experiment in metabolic engineering of stress tolerance . Proc. Natl. Acad. Sci. USA. 91:1994;306-310.
17. Holme E., Greter J., Jacobson C.E., Lindstedt S., Nordin I., Kristiansson B., Jodal U. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 2:1989;469-472.
18. Shimizu K., Saito A., Shimada J., Ohmichi M., Hiraga Y., Inamatsu T., Shimada K., Tanimura M., Fujita Y., Nishikawa T., Oguma T., Yamamoto S. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob. Agents Ch. 37:1993;1043-1049.
19. Totsuka K., Shimizu K., Konishi M., Yamamoto S. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob. Agents Ch. 36:1992;757-761.
20. Ruff L.J., Brass E.P. Metabolic effects of pivalate in isolated rat hepatocytes. Toxicol. Appl. Pharm. 110:1991;295-302.
21. Engel A.G., Rebouche C.J. Carnitine metabolism and inborn errors. J. Inherit. Metab. Dis. 7:(suppl 1):1984;38-43.
22. Kerner J., Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Annu. Rev. Nutr. 18:1998;179-206.
23. Abrahamsson K., Mellander M., Eriksson B.O., Holme E., Jodal U., Jonsson A., Lindstedt S. Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid. Brit. Heart. J. 74:1995;656-659.